The Modern Aspects of Immune Corrective Therapy in Patients with Chronic Obstructive Pulmonary Disease with Metabolic Syndrome
Svitlana A. Bychkova
Chronic obstructive pulmonary disease (COPD), along with hypertension, ischemic heart disease and diabetes is a leading a group of chronic diseases, which account for over 30% of all other human pathology. The leading cause of mortality in patients with light and medium heavy flow COPD is not respiratory failure, as traditionally believed, but cardiovascular disease - hypertension, coronary heart disease, which are components of the metabolic syndrome (Met S). The purpose of study was to identify clinical and immunological effectiveness of atorvastatin and polyoxidonium in patients with COPD, combined with Met S. The study involved 75 patients with COPD stage II and Met S. Some immunological tests of I and II levels were performed before and after treatment by statins. The combined use of atorvastatin and polyoxidonium shows significant clinical and immunological efficacy, which is to restore the values of healthy individuals phagocytic activity of neutrophils, reducing autoimmune manifestations, phenomena of auto sensibilization and has powerful anti-inflammatory properties.
How to cite this article:
Svitlana A. Bychkova. The Modern Aspects of Immune Corrective Therapy in Patients with Chronic Obstructive Pulmonary Disease with Metabolic Syndrome. Pharma Innovation 2013;2(10):47-52.